Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
PubblicatoJoella Stephens Modificato 5 anni fa
1
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C.F. Magni, S. Paolucci, S. Babudieri, M. Siciliano, C. Pasquazzi, A. Ciancio, C.F. Perno, F. Ceccherini-Silberstein V. Micheli, Y. Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L. Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco, V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, C. Sarrecchia, M. Macera, N. Coppola, M. Puoti, D. Romagnoli, A. Pellicelli, S. Bonora, S. Novati, F. Baldanti, V. Ghisetti, M. Andreoni, G. Taliani, G. Rizzardini, M. Angelico V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C.F. Magni, S. Paolucci, S. Babudieri, M. Siciliano, C. Pasquazzi, A. Ciancio, C.F. Perno, F. Ceccherini-Silberstein V. Micheli, Y. Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L. Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco, V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, C. Sarrecchia, M. Macera, N. Coppola, M. Puoti, D. Romagnoli, A. Pellicelli, S. Bonora, S. Novati, F. Baldanti, V. Ghisetti, M. Andreoni, G. Taliani, G. Rizzardini, M. Angelico Clinical Microbiology and Infection Volume 23, Issue 10, Pages 777.e1-777.e4 (October 2017) DOI: /j.cmi Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions
2
Fig. 1 SVR12 rates in patient subgroups. SVR12 rates obtained in protease-inhibitor experienced patients retreated with interferon-free regimens chosen according to GRT, EASL/AASLD recommendations, or none of them. Rates are reported separately for each drug combination, ribavirin use and duration. The number of patients who relapsed, or presented resistance-associated substitutions at baseline are shown. 3D, paritaprevir/ritonavir, ombitasvir and dasabuvir; AASLD, American Association for the Study of Liver Diseases; DCV, daclatasvir; EASL, European Association for the Study of the Liver; GRT, genotypic-resistance-test; IFN, interferon; LDV, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR12, sustained virological response; RAS, resistance-associated substitution. Clinical Microbiology and Infection , 777.e1-777.e4DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions
Presentazioni simili
© 2024 SlidePlayer.it Inc.
All rights reserved.